Putting Price Action Altogether | BIOCON LIMITED

⚡️ Investing opportunity: Price Action Analysis Alert !!!⚡️
⚠️Education Purpose only!!!!

1️⃣Biocon Limited Overview

📍Founded: 1978 by Kiran Mazumdar-Shaw
📍Headquarters: Bengaluru, Karnataka, India
📍Markets: Over 120 countries, including the United States and Europe

2️⃣Key Business Divisions
👉Generics: Produces generic APIs for global markets.
👉Biosimilars: Focuses on biosimilar insulins and monoclonal antibodies.
👉Research Services: Contract research and development via subsidiary Syngene International.
👉Novel Biologics: Develops innovative therapies for diseases like cancer, diabetes, and autoimmune disorders.

3️⃣Financial Performance
✅Net Loss: ₹160 million
✅Revenue: ₹35.9 billion, up 3.7% YoY.
✅Biosimilars Revenue: Increased by 11% (U.S., Europe).
✅Generics Revenue: Declined by 7.7%

4️⃣Technical Reasons to trade or Strategy applied :-
⭕️50 Day Moving averages shows strong Bullishness in Long-Term
⭕️Head&Shoulder Pattern Breakout
⭕️Breakout with strong Volume
⭕️Channel Pattern Formation
⭕️Upward Trendline for Resistance
⭕️Higher-Lows Formation before Breakout
⭕️Trendline Breakout too

5️⃣Key Takeaways
⚠️Strengths: Strong global presence and diverse biopharmaceutical portfolio.
⚠️Challenges: Recent profitability concerns due to pricing pressures and tax adjustments.
⚠️Growth Potential: Biosimilars and novel biologics present significant long-term opportunities.
⚠️Investor Consideration: Combine fundamental and technical analyses to assess investment decisions.


✅Check out my Trading View profile to see how we analyze charts and execute trades.

🙋‍♀️🙋‍♂️If you have any questions about this stock, feel free to reach out to me.

📍📌Thank you for exploring our idea! We hope you found it valuable.

🙏FLLOW for more !
👍LIKE if useful !
✍️COMMENT Below your view